Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study

Open Label ◽

Preliminary Results ◽

Open Label Phase ◽

Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Preliminary results of an open-label phase II clinical study

Annals of Oncology ◽

10.1093/annonc/mdy288.023 ◽

2018 ◽

Vol 29 ◽

pp. viii409 ◽

Cited By ~ 1

Author(s):

R. Xu ◽

F.H. Wang ◽

F.J. Feng ◽

Q. Li ◽

N. Xu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Clinical Study ◽

Phase Ii ◽

Open Label ◽

Preliminary Results ◽

Open Label Phase ◽

Phase Ii Clinical Study

Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with refractory/metastatic urothelial carcinoma: Preliminary results of an open-label phase II clinical study

European Urology Open Science ◽

10.1016/s2666-1683(20)33652-1 ◽

2020 ◽

Vol 19 ◽

pp. e1579

Author(s):

H. Chen ◽

X. Sheng ◽

R. Zhang ◽

B. Hu ◽

X. Yao ◽

...

Keyword(s):

Monoclonal Antibody ◽

Clinical Study ◽

Urothelial Carcinoma ◽

Phase Ii ◽

Open Label ◽

Preliminary Results ◽

Open Label Phase ◽

Phase Ii Clinical Study ◽

Metastatic Urothelial Carcinoma

Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial

Annals of Oncology ◽

10.1093/annonc/mdz020 ◽

2019 ◽

Vol 30 (4) ◽

pp. 637-643 ◽

Cited By ~ 13

Author(s):

C. Zhao ◽

J. Miao ◽

G. Shen ◽

J. Li ◽

M. Shi ◽

...

Keyword(s):

Clinical Trial ◽

Monoclonal Antibody ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Radical Radiotherapy ◽

Open Label ◽

Open Label Phase ◽

Epidermal Growth

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30169-9 ◽

2017 ◽

Vol 18 (5) ◽

pp. 623-630 ◽

Cited By ~ 227

Author(s):

Evan W Alley ◽

Juanita Lopez ◽

Armando Santoro ◽

Anne Morosky ◽

Sanatan Saraf ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Open Label ◽

Clinical Safety ◽

Preliminary Results ◽

Open Label Phase ◽

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial

ESMO Open ◽

10.1016/j.esmoop.2021.100313 ◽

2021 ◽

Vol 6 (6) ◽

pp. 100313

Author(s):

T. Zhou ◽

Y. Yang ◽

S. Ma ◽

L. Lin ◽

T. Zhou ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(16)31388-5 ◽

2016 ◽

Vol 388 (10054) ◽

pp. 1883-1892 ◽

Cited By ~ 146

Author(s):

Li Zhang ◽

Yan Huang ◽

Shaodong Hong ◽

Yunpeng Yang ◽

Gengsheng Yu ◽

...

Keyword(s):

Open Label ◽

Phase 3 ◽

Open Label Phase

Faculty Opinions recommendation of Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727407783.793551916 ◽

2018 ◽

Author(s):

Paul Van Schil

Keyword(s):

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Open Label ◽

Clinical Safety ◽

Preliminary Results ◽

Open Label Phase ◽

First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial

Annals of Oncology ◽

10.1093/annonc/mdx374.009 ◽

2017 ◽

Vol 28 ◽

pp. v376-v377

Author(s):

L. Zhang ◽

Y. Huang ◽

Y. Yang ◽

S. Ma ◽

X. Lin ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Trial ◽

First Line ◽

Open Label ◽

Open Label Phase

Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients (pts) with platinum-refractory germ cell tumors (GCT): Preliminary results from an open label phase 1b study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e16545 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e16545-e16545

Author(s):

Neda Hashemi-Sadraei ◽

Lawrence H. Einhorn ◽

Susan Perkins ◽

Michael J Spinella ◽

Fang Fang ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumors ◽

Open Label ◽

Preliminary Results ◽

Open Label Phase ◽

Platinum Refractory ◽

Chemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial

Annals of Oncology ◽

10.1093/annonc/mdz252 ◽

2019 ◽

Vol 30 ◽

pp. v449 ◽

Cited By ~ 2

Author(s):

M. Chen ◽

R. You ◽

L. You-Ping ◽

P.-Y. Huang ◽

X. Zou ◽

...

Keyword(s):

Phase Iii ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase